Precigen PGEN touts strong Q2 growth; PRGN-2009 HPV-cancer progress
Precigen (PGEN) reports a strong second quarter, saying it signals significant growth and validates its AdenoVerse platform, while highlighting PRGN-2009 advances in HPV-driven cancers.